Dasatinib as first-line treatment for adult patients

Dasatinib as first-line treatment for adult patients with
Philadelphia chromosome–positive acute lymphoblastic
leukemia
by Robin Foà, Antonella Vitale, Marco Vignetti, Giovanna Meloni, Anna Guarini,
Maria Stefania De Propris, Loredana Elia, Francesca Paoloni, Paola Fazi, Giuseppe
Cimino, Francesco Nobile, Felicetto Ferrara, Carlo Castagnola, Simona Sica, Pietro
Leoni, Eliana Zuffa, Claudio Fozza, Mario Luppi, Anna Candoni, Ilaria Iacobucci,
Simona Soverini, Franco Mandelli, Giovanni Martinelli, Michele Baccarani, and
Blood
Volume 118(25):6521-6528
December 15, 2011
©2011 by American Society of Hematology
BCR-ABL transcript levels during dasatinib therapy.
Robin Foà et al. Blood 2011;118:6521-6528
©2011 by American Society of Hematology
Survival curves.
Robin Foà et al. Blood 2011;118:6521-6528
©2011 by American Society of Hematology
DFS according to BCR-ABL transcript reduction during dasatinib treatment.
Robin Foà et al. Blood 2011;118:6521-6528
©2011 by American Society of Hematology
DFS according to immunophenotype evaluation at day 85.
Robin Foà et al. Blood 2011;118:6521-6528
©2011 by American Society of Hematology